Bispecific Binding Agents Modulating CD8+KIR+ Treg Activity
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current technologies lack effective methods to modulate the activity of CD8+KIR+ regulatory T cells (Tregs), which are crucial for maintaining immune balance and preventing autoimmune disorders, infectious diseases, and cancer.
Innovation Solution
Development of bispecific or multi-specific binding agents that specifically bind to antigens expressed on CD8+KIR+ Tregs, including CD3, CD8, and inhibitory KIR proteins, to modulate their activity.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Measurement precision
If conventional monoclonal antibodies are used to target immune cells, then specificity to a single antigen is achieved, but the ability to modulate complex Treg activity is insufficient
Solution Approach 1:
The patent combines multiple antigen-binding specificities into a single bispecific antibody molecule. The antibody simultaneously binds to CD3 (a pan-T cell marker) and to inhibitory KIR proteins (such as KIR2DL1, KIR2DL2, KIR2DL3, or KIR3DL1) expressed on CD8+KIR+ Tregs. This merging of functions allows the single agent to engage multiple targets on or associated with Tregs, thereby modulating their activity more effectively than conventional monoclonal antibodies while maintaining high specificity through engineered binding domains.
Solution Approach 2:
The bispecific antibody serves multiple functions simultaneously: it acts as a Treg-specific binding agent, modulates inhibitory KIR signaling pathways, and can recruit additional immune cells through Fc region interactions. The antibody is designed to bind to antigens that are universally expressed on Treg populations (CD3, CD8) while also targeting the inhibitory KIR receptors that regulate Treg function, thereby providing universal applicability across different Treg-mediated pathological conditions including autoimmune diseases, infectious diseases, and cancer.
2Adaptability or versatility
If broad-spectrum immunosuppressive agents are used to control immune responses, then immune balance is maintained, but specificity to pathogenic Tregs is lost and off-target effects occur
Solution Approach 1:
The bispecific antibody is designed to target specific local features of pathogenic Tregs rather than broadly suppressing all immune cells. By simultaneously binding to CD3 (present on all T cells) and to inhibitory KIR proteins (specifically expressed on certain Treg subsets), the antibody achieves localized modulation of Treg activity. This local quality approach allows selective engagement of pathogenic Tregs that express the target KIR proteins while sparing other immune cell populations, thereby maintaining immune response regulation without the off-target effects associated with broad-spectrum immunosuppressants.
3Reliability
If existing Treg modulation methods are used, then some immune control is achieved, but effective therapeutic benefit for autoimmune diseases and cancer is not realized
Solution Approach 1:
The bispecific antibody acts as an intermediary agent that bridges multiple components of the immune system to achieve effective Treg modulation. It simultaneously engages Treg cells (through CD3 and CD8 binding), inhibitory KIR receptors (which mediate immune suppression), and potentially Fc receptor-bearing immune cells (through Fc region interactions). This intermediary function allows the antibody to orchestrate complex immune interactions, converting the inhibitory signals from KIR binding into therapeutic effects that control autoimmune diseases and enhance anti-tumor immunity, thereby achieving both reliable immune control and meaningful therapeutic benefit.
Data Source
AI summary
The present invention provides binding agents that specifically bind to CD8+KIR+ T regulatory cells and their use in the treatment of diseases or disorders, such as an inflammatory disease, an autoimmune disease, cancer, or an infectious disease.